The EMPA-REG OUTCOME trial, DAPA-HF trial, CVD-REAL trial, EMPEROR-Reduced and the VERTIS CV trial, have all shown that SGLT2 lowers the risk of HF, renal impairment, and overall mortality [47,48,49,50,51,52,53,54]. The gene discussed is SLC5A2; the disease is hydrops fetalis.